Brief: Valeo Pharma Files New Drug Submission-Covid 19 With Health Canada
26/01/2023 12:17
Jan 26 (Reuters) - Valeo Pharma Inc VPH.TO :
* VALEO PHARMA ANNOUNCES FILING OF A NEW DRUG
SUBMISSION-COVID 19
WITH HEALTH CANADA FOR SABIZABULIN FOR THE TREATMENT OF
HOSPITALIZED COVID-19 PATIENTS
* VALEO PHARMA INC - SABIZABULIN ALSO SHOWED A SIGNIFICANT
REDUCTION OF DAYS IN ICU, DAYS ON MECHANICAL VENTILATION AND
DAYS IN HOSPITAL
Source text for Eikon: ID:nCNWvzltSa
Further company coverage: VPH.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Valeo Pharma
See all newsBrief: Valeo Pharma Says Co Initiates Restructuring Proceedings
Brief: Valeo Pharma Amends Credit Facility With Sagard Healthcare Royalty Partners
Brief: Valeo Pharma Announces Restructuring Of Commercial Field Operations To Support Path To Profitability
Brief: Valeo Pharma Announces Appointment Of Mr. Al Moghaddam To Board Of Directors
Brief: Valeo Pharma Amends Agreement With Novartis Pharmaceuticals Canada